Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

Inclusion Criteria: * Adult over 19years * Patients with primary hypercholesterolemia whose LDL-C level is below 250mg/dL and TG level is below 350mg/dL * Patients whose LDL-C level is under 'Anti- dyslipidemia drug administration considered standard' of NCEP ATP III(2004) * Those who voluntarily written consent to participate in this clinical trial Exclusion Criteria: * Uncontrolled hypertension * Severe renal impairment(CrCl\<30mL/min) * Those who have active liver disease and whose ALT, AST levels greater than twice the upper limit of normal * Serum creatinine \> 2.0mg/dL * Those who have been geunyukbyeong or rhabdomyolysis caused by using statin or have hypersensitivity to ezetimibe * Combined cyclosporine -treated patients * HbA1c ≥ 9% * TSH ≥ 1.5 X ULN * HIV-positive person * Congestive heart failure patients classified as NYHA Class III or IV * Patients with uncontrolled arrhythmias * Patients who have malignant tumors needed chemotherapy, radiation therapy, etc. * Blood clotting disorders * Patients who had a myocardial infarction within 6 months or cardiovascular bypass surgery, patients who have underwent angioplasty * Patients who had a history of anxiety or severe typical peripheral arterial disease within three months * Women of childbearing age who don't agree with contraception during this clinical trials * Pregnant women or nursing mothers * Those who take the drug in combination taboo * Who have been treated for another investigational drug within 30 days * Unsuitable characters in a clinical trial to test self- determination